ReviewFrontiers in cell and developmental biology2025
Umbrella review of mesenchymal stem cell-derived extracellular vesicles in preclinical models: therapeutic efficacy across diverse conditions.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Exosomes and Small Extracellular Vesicles as an Alternative to Mesenchymal Stromal Cell Therapy in Knee Osteoarthritis: From Biological Rationale to Clinical Evidence.International journal of molecular sciences · 2026Review
- Stem Cells and Their Derivatives in Cardiac Fibrosis Therapy: Challenges and Perspectives.Cells · 2026Review
- Extracellular Vesicles in Obesity: From Pathophysiological Mediators to Therapeutic Tools.International journal of molecular sciences · 2026Review
- Preclinical models of stem cell-mediated analgesia and tissue repair: mechanisms, challenges, and future directions.Frontiers in cellular neuroscience · 2026Review
- The Current Application Prospects of Nanomedicine in Renal Ischemia-Reperfusion Injury.International journal of nanomedicine · 2026Review
- Beyond wound closure: translational opportunities and barriers of mesenchymal stem cells and their extracellular vesicles in burn management.Frontiers in cell and developmental biology · 2026Review
- Extracellular vesicle-based therapies for neurodegenerative diseases.NeuroImmune pharmacology and therapeutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) have emerged as a promising cell-free therapeutic strategy for various diseases due to their anti-inflammatory, anti-apoptotic, and regenerative properties. Numerous meta-analyses have evaluated MSC-EV efficacy in preclinical animal models, but a comprehensive synthesis across diverse conditions is lacking. Objective: This umbrella review aims to systematically evaluate the therapeutic efficacy, mechanisms, and methodological quality of MSC-EVs in preclinical models across multiple diseases. Methods: A systematic search of Scopus and Web of Science was conducted to identify meta-analyses published up to July 2025, focusing on MSC-EV interventions in preclinical animal models. Data were extracted on study characteristics, exosome sources, animal models, outcomes, and risk of bias. The AMSTAR 2 tool assessed meta-analysis quality, while SYRCLE and CAMARADES tools evaluated primary study bias. Narrative and quantitative syntheses summarized efficacy, heterogeneity, and publication bias. Results: Forty-seven meta-analyses covering 27 diseases were included, spanning neurological, renal, wound healing, liver, musculoskeletal, respiratory, and reproductive disorders. MSC-EVs demonstrated high efficacy, significantly improving functional scores, reducing inflammation, and promoting regeneration. Bone marrow-, adipose-, and umbilical cord-derived EVs were most effective, with modified EVs showing enhanced outcomes. Methodological quality was moderate (AMSTAR 2), with high heterogeneity (I Conclusion: MSC-EVs exhibit robust therapeutic potential across diverse preclinical models, supporting their development as a versatile regenerative therapy. Standardization of EV protocols, improved study quality, and mechanistic insights are critical for clinical translation. This review provides a comprehensive framework for advancing MSC-EV research and application.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.